OTCM
INCPF
Market cap2.39bUSD
Aug 04, Last price
3.26USD
Name
InnoCare Pharma Ltd
Chart & performance
P/E
51.86
P/S
14.13
EPS
0.42
Vol. 1Y
—
Shs. 5Y
12.74%
Rev. 5Y
341.86%
Div Yld LY
—
Div Yld TTM
—
Revenues
2.30b
+127.60%
Net income
626m
P
CFO
199m
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
InnoCare Pharma Limited, a biopharmaceutical enterprise, specializes in the discovery, development, and commercialization of therapeutic agents for oncological and autoimmune disorders. Its lead product, Orelabrutinib, a BTK inhibitor, addresses a wide range of conditions, including various forms of relapsed and/or refractory (r/r) lymphomas (such as chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, specific diffuse large B-cell lymphomas, and central nervous system lymphoma). It also targets systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder, sometimes utilized in combination therapies. The company's robust pipeline features several key candidates: ICP-192, a pan-FGFR inhibitor in Phase I/II clinical trials for solid tumors, notably cholangiocarcinoma and head and neck cancer; ICP-723, a pan-TRK inhibitor undergoing Phase I evaluation for cancers positive for neurotrophic tyrosine receptor kinase fusion; ICP-332, a novel tyrosine kinase 2 inhibitor in Phase I for autoimmune diseases; and ICP-B02, a bispecific antibody developed for lymphoma treatment. Furthermore, InnoCare is advancing ICP-189, ICP-915, and ICP-B03 for solid tumors; ICP-033 for liver cancer, renal cell carcinoma, colorectal cancer, and other solid malignancies; ICP-488 for autoimmune conditions; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody targeting various cancers; ICP-248 for hematological indications; and ICP-490 for both hematology and autoimmune disorders. In addition, the firm offers ICP-B04 (Tafasitamab) for the treatment of DLBCL and other hematological conditions. InnoCare Pharma Limited was established in 2015 and maintains its headquarters in Beijing, China.
Key people
Shaojing Tong
Chief Financial Officer
Nan Gao
Chief Operation Officer
Xiangyang Chen
Chief Technology Officer
Junsu Wang
General Manager
Jisong Cui
Executive Chairman of the Board, Chief Executive Officer · since 2019
Renbin Zhao
Executive Director · since 2019
Xiaodong Jin
Chief Commercial Officer
Xiang-Yang Zhang
Chief Medical Officer · since 2021
Pui Shan Lee
Company Secretary · since 2022
Ming Jin
Non-Executive Director · since 2022
Yigong Shi
Non-Executive Director · since 2018
Ronggang Xie
Non-Executive Director · since 2021
Kaixian Chen
Non-Executive Independent Director · since 2020
Dandan Dong
Independent Non-Executive Director · since 2023
Kunliang Guan
Independent Non-Executive Director · since 2025
Lan Hu
Non-Executive Independent Director · since 2020
Headquarters & legal address
89 Nexus Way
Camana Bay
Grand Cayman KY1-9009
KY
Camana Bay
Grand Cayman KY1-9009
KY
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||